Across the country, a number of state legislatures have considered enacting prescription drug affordability boards (PDABs). While the intention might be to lower costs, the implementation of these price control boards has adverse effects on patients’ access to medicines they depend on, especially to manage rare and chronic conditions.
Dr. Harry Gewanter – a highly accomplished pediatric rheumatologist and Board member of Let My Doctors Decide Action Network – conveyed this message to Virginia Governor Glenn Youngkin in a letter signed by more than 70 doctors. As Virginia’s lawmakers consider instituting a PDAB, Dr. Gewanter and colleagues explained how such a proposal would fail to lower costs while restricting access to vital medicines, jeopardizing patients’ health and well-being.
In addition, Dr. Gewanter shared this message in a 30-second TV ad. Watch the full video below to learn more about the unintended consequences of PDABs.